Terumo (OTCMKTS:TRUMY) Upgraded by Nomura to “Strong-Buy” Rating

Nomura upgraded shares of Terumo (OTCMKTS:TRUMY) from a hold rating to a strong-buy rating in a research report released on Thursday,Zacks.com reports.

Separately, Zacks Research upgraded Terumo to a “hold” rating in a research report on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Terumo presently has an average rating of “Buy”.

Terumo Price Performance

Shares of TRUMY opened at $14.53 on Thursday. The company has a market capitalization of $21.43 billion, a price-to-earnings ratio of 23.82 and a beta of 0.68. Terumo has a 1 year low of $12.08 and a 1 year high of $19.60. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.59 and a quick ratio of 0.97. The business has a 50-day moving average of $14.01 and a 200-day moving average of $13.54.

Terumo (OTCMKTS:TRUMY) last released its earnings results on Friday, May 15th. The company reported $0.11 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.11. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.84 billion. Terumo had a net margin of 12.09% and a return on equity of 9.17%. As a group, equities research analysts anticipate that Terumo will post 0.7 earnings per share for the current year.

Terumo Company Profile

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.